However, there was a statistical trend towards an OS improvement by adding cetuximab to the gemcitabine maintenance therapy (study arm B), although a statistical significance could not be achieved.
← all excerpts
Cetuximab, gemcitabine and radiotherapy in locally advanced pancreatic cancer: Long-term results of the randomized controlled phase II PARC trial.
1
—
—